NASDAQ$TXG
10X Genomics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported a 170% increase in revenue compared to the prior year and a 9% increase compared to the prior quarter.
10x Genomics reported strong second-quarter results, with revenue reaching $115.8 million, a 170% increase year-over-year. The company launched Chromium X and began shipping Visium Spatial Gene Expression for FFPE, and settled litigation with Bio-Rad Laboratories, Inc.
- Revenue was $115.8 million for the second quarter, representing a 170% increase over the corresponding period of 2020 and a 9% increase compared to the first quarter of 2021.
- Launched Chromium X, a next-generation instrument and platform for single cell analysis enabling million cell experiments and accelerating discoveries.
- Began shipping Visium Spatial Gene Expression for FFPE, a new assay that gives researchers access to whole transcriptome spatial profiling of preserved tissue blocks.
- Entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. resolving all outstanding litigation.
Headline financials
Revenue & EPS history
10X Genomics · Revenue · Quarterly
$116M
Revenue by segment
10X Genomics · $149M total across 4 segments · Q3 2023
- Single Cell Consumables$100M—67.2%
- Spatial Instruments$22.7M—15.2%
- Spatial Consumables$14.1M—9.4%
- Single Cell Instruments$12.2M—8.2%
Forward guidance
10x Genomics is maintaining its previously announced full year 2021 revenue guidance of $480 million to $500 million, representing 61% to 67% growth over full year 2020 revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.1%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+2.0%
Avg return
30 days after
58%
15 / 26 earnings
Positive
+17.3%
Q3 2025
Best reaction
-21.9%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.6% | -5.9% | +38.4% | |
| Q4 2025 | +3.5% | +11.8% | +7.3% | |
| Q3 2025 | +17.3% | +28.4% | +36.7% | |
| Q1 2025 | +1.3% | +5.7% | +9.2% | |
| Q4 2024 | -0.5% | +0.6% | -13.8% | |
| Q3 2024 | +4.0% | +3.0% | -2.4% | |
| Q2 2024 | +12.7% | +18.8% | +18.8% | |
| Q1 2024 | -5.2% | -3.2% | -21.1% | |
| Q4 2023 | +0.8% | -1.3% | -24.4% | |
| Q3 2023 | +15.7% | +13.7% | +33.3% | |
| Q2 2023 | -4.5% | -7.7% | -7.9% | |
| Q1 2023 | +5.9% | +5.5% | +5.7% | |
| Q4 2022 | +14.8% | +15.2% | +7.5% | |
| Q3 2022 | +13.0% | +9.5% | +38.1% | |
| Q2 2022 | +5.4% | +13.2% | -24.0% | |
| Q1 2022 | -0.5% | -6.4% | -10.6% | |
| Q4 2021 | -15.0% | -14.4% | -26.7% | |
| Q3 2021 | +12.7% | +7.7% | -14.9% | |
| Q2 2021 | -1.8% | -3.3% | +3.7% | |
| Q1 2021 | -21.9% | -27.1% | -2.6% | |
| Q4 2020 | -3.1% | -7.1% | -7.6% | |
| Q3 2020 | +1.8% | +3.3% | +11.4% | |
| Q2 2020 | +0.6% | +6.0% | +17.1% | |
| Q1 2020 | -0.4% | -6.0% | +3.1% | |
| Q4 2019 | -2.1% | -11.4% | -40.6% | |
| Q3 2019 | +3.1% | +10.3% | +17.3% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro